Warther Private Wealth LLC Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Warther Private Wealth LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 90.1% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 464 shares of the biopharmaceutical company's stock after selling 4,200 shares during the period. Warther Private Wealth LLC's holdings in Regeneron Pharmaceuticals were worth $294,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Traphagen Investment Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 11.9% in the first quarter. Traphagen Investment Advisors LLC now owns 770 shares of the biopharmaceutical company's stock valued at $488,000 after acquiring an additional 82 shares in the last quarter. Asio Capital LLC boosted its holdings in Regeneron Pharmaceuticals by 13.6% in the 1st quarter. Asio Capital LLC now owns 3,995 shares of the biopharmaceutical company's stock valued at $2,534,000 after purchasing an additional 477 shares in the last quarter. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 5.8% in the 1st quarter. Brighton Jones LLC now owns 1,003 shares of the biopharmaceutical company's stock valued at $636,000 after purchasing an additional 55 shares in the last quarter. Factory Mutual Insurance Co. increased its position in Regeneron Pharmaceuticals by 210.3% during the 1st quarter. Factory Mutual Insurance Co. now owns 12,100 shares of the biopharmaceutical company's stock worth $7,674,000 after purchasing an additional 8,200 shares during the period. Finally, Ritholtz Wealth Management increased its position in Regeneron Pharmaceuticals by 7.8% during the 1st quarter. Ritholtz Wealth Management now owns 486 shares of the biopharmaceutical company's stock worth $308,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on REGN. Royal Bank of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research note on Friday, May 30th. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a report on Monday, June 2nd. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Finally, UBS Group decreased their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a report on Thursday, June 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $836.48.

Regeneron Pharmaceuticals Trading Down 1.2%

REGN stock traded down $6.56 on Monday, hitting $522.68. 1,324,809 shares of the company were exchanged, compared to its average volume of 881,131. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $56.43 billion, a price-to-earnings ratio of 13.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The business's fifty day moving average is $563.19 and its two-hundred day moving average is $648.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the company earned $9.55 earnings per share. The company's quarterly revenue was down 3.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.